{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:34:29Z","timestamp":1724308469053},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die transrektale Prostatastanzbiopsie (TRPB) geh\u00f6rt zu den h\u00e4ufigsten interventionell-urologischen Eingriffen in Deutschland. Es wird leitliniengerecht eine kurzeitige periprozedurale Antibiotikaprophylaxe (PAP) empfohlen. Die Indikationsr\u00fccknahme von Fluorchinolonen als PAP-Substanz durch das Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte macht die Verwendung alternativer Substanzen notwendig.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziele<\/jats:title>\n                <jats:p>Im Rahmen der Studie wurde die klinische Praxis der PAP bei TRPB mit Fokus auf infekti\u00f6se Komplikationen im Vergleich zwischen Fluorchinolon- und Cotrimoxazol-PAP evaluiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Es handelt sich um eine retrospektive monozentrische Auswertung klinischer Routinedaten von Patienten mit TRPB zwischen 03.01.2019 und 28.01.2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Es wurden 508 erwachsene m\u00e4nnliche Patienten eingeschlossen, das mediane Alter betrug 68\u00a0Jahre. 55,9\u202f% erhielten eine Cotrimoxazol-PAP, 40,0\u202f% eine Fluorchinolon-PAP. Insgesamt traten in 5,5\u202f% postinterventionelle Komplikationen auf, davon 50,0\u202f% infekti\u00f6se Komplikationen. Der Vergleich von Cotrimoxazol- und Fluorchinolon-PAP ergab keinen Unterschied der Komplikationsraten. Bei aufgrund von Komplikationen durchgef\u00fchrten mikrobiologischen Urinuntersuchungen zeigten sich Erregernachweise mit Resistenz gegen\u00fcber der zuvor eingesetzten PAP im Sinne einer Selektion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Eine Cotrimoxazol-PAP f\u00fcr TRPB ist verglichen mit dem bisherigen Standard einer Fluorchinolon-PAP nicht mit vermehrt infekti\u00f6sen Komplikationen assoziiert. Die pr\u00e4interventionelle Analyse von Keimspektrum und Resistenz erm\u00f6glicht den Einsatz einer gezielten Prophylaxe und kann somit Komplikationen reduzieren.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00120-021-01618-1","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T17:03:07Z","timestamp":1629306187000},"page":"160-166","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibiotikaprophylaxe bei transrektaler Prostatabiopsie"],"prefix":"10.1007","volume":"61","author":[{"given":"Kathrin","family":"Rothe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Querbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk H.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Hauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"1618_CR1","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1093\/jac\/dku293","volume":"69","author":"V Antsupova","year":"2014","unstructured":"Antsupova\u00a0V, N\u00f8rgaard\u00a0N, Bisbjerg\u00a0R et\u00a0al (2014) Antibiotic prophylaxis for transrectal prostate biopsy\u2014a new strategy. J\u00a0Antimicrob Chemother 69:3372\u20133378","journal-title":"J Antimicrob Chemother"},{"key":"1618_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1046\/j.1464-410x.2000.00576.x","volume":"85","author":"M Aron","year":"2000","unstructured":"Aron\u00a0M, Rajeev\u00a0TP, Gupta\u00a0NP (2000) Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a\u00a0randomized controlled study. BJU Int 85:682\u2013685","journal-title":"BJU Int"},{"key":"1618_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5152\/tud.2015.22120","volume":"41","author":"D At\u0131lgan","year":"2015","unstructured":"At\u0131lgan\u00a0D, Gen\u00e7ten\u00a0Y, K\u00f6l\u00fck\u00e7\u00fc\u00a0E et al (2015) Comparison between ciprofloxacin and trimethoprim-sulfamethoxazole in antibiotic prophylaxis for transrectal prostate biopsy. Turk J Urol 41:27\u201331","journal-title":"Turk J Urol"},{"key":"1618_CR4","series-title":"AUA guideline","volume-title":"AUA quality improvement summit 2014: conference proceedings on infectious complications of transrectal prostate needle biopsy","author":"T Averch","year":"2014","unstructured":"Averch\u00a0T et\u00a0al (2014) AUA quality improvement summit 2014: conference proceedings on infectious complications of transrectal prostate needle biopsy. AUA guideline"},{"key":"1618_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fsurg.2018.00002","volume":"5","author":"K Boehm","year":"2018","unstructured":"Boehm\u00a0K, Siegel\u00a0FP, Schneidewind\u00a0L et\u00a0al (2018) Antibiotic prophylaxis in prostate biopsies: contemporary practice patterns in Germany. Front Surg 5:2","journal-title":"Front Surg"},{"key":"1618_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eururo.2016.08.004","volume":"71","author":"M Borghesi","year":"2017","unstructured":"Borghesi\u00a0M, Ahmed\u00a0H, Nam\u00a0R et al (2017) Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 71:353\u2013365","journal-title":"Eur Urol"},{"key":"1618_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","volume":"35","author":"T Cai","year":"2017","unstructured":"Cai\u00a0T, Gallelli\u00a0L, Cocci\u00a0A et al (2017) Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol 35:221\u2013228","journal-title":"World J Urol"},{"key":"1618_CR8","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1128\/JCM.00144-16","volume":"54","author":"RR Chamberland","year":"2016","unstructured":"Chamberland\u00a0RR (2016) Cutting to the core of the issue: emerging strategies to reduce prostate biopsy-related infections. J\u00a0Clin Microbiol 54:2431\u20132435","journal-title":"J Clin Microbiol"},{"key":"1618_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1046\/j.1464-410X.2002.02991.x","volume":"90","author":"L Cormio","year":"2002","unstructured":"Cormio\u00a0L, Berardi\u00a0B, Callea\u00a0A et\u00a0al (2002) Antimicrobial prophylaxis for transrectal prostatic biopsy: a\u00a0prospective study of ciprofloxacin vs piperacillin\/tazobactam. BJU Int 90:700\u2013702","journal-title":"BJU Int"},{"key":"1618_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000502851","volume":"103","author":"C D\u2019Elia","year":"2019","unstructured":"D\u2019Elia\u00a0C, Mian\u00a0C, Hanspeter\u00a0E et\u00a0al (2019) Efficacy and safety of two fosfomycin regimens as antimicrobial prophylaxis for transrectal prostate biopsy: a randomised study. Urol Int 103:433\u2013438","journal-title":"Urol Int"},{"key":"1618_CR11","doi-asserted-by":"publisher","first-page":"e010077","DOI":"10.1136\/bmjopen-2015-010077","volume":"5","author":"N Daneman","year":"2015","unstructured":"Daneman\u00a0N, Lu\u00a0H, Redelmeier\u00a0DA (2015) Fluoroquinolones and collagen associated severe adverse events: a\u00a0longitudinal cohort study. BMJ Open 5:e10077","journal-title":"BMJ Open"},{"key":"1618_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.urology.2011.09.057","volume":"79","author":"CA Duplessis","year":"2012","unstructured":"Duplessis\u00a0CA, Bavaro\u00a0M, Simons\u00a0MP et al (2012) Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 79:556\u2013561","journal-title":"Urology"},{"key":"1618_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","volume":"53","author":"ME Falagas","year":"2019","unstructured":"Falagas\u00a0ME, Athanasaki\u00a0F, Voulgaris\u00a0GL et\u00a0al (2019) Resistance to fosfomycin: mechanisms, frequency and clinical consequences. Int J Antimicrob Agents 53:22\u201328","journal-title":"Int J Antimicrob Agents"},{"key":"1618_CR14","volume-title":"2015 EAU guidlines on urological infections long version","author":"M Grabe","year":"2015","unstructured":"Grabe\u00a0M, Bartoletti\u00a0R, Bjerklund Johansen\u00a0T et\u00a0al (2015) 2015 EAU guidlines on urological infections long version"},{"key":"1618_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41391-020-0204-8","volume":"23","author":"J Grummet","year":"2020","unstructured":"Grummet\u00a0J, Gorin\u00a0MA, Popert\u00a0R et\u00a0al (2020) \u201eTREXIT 2020\u201c: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis 23:62\u201365","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1618_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.juro.2010.11.088","volume":"185","author":"MA Liss","year":"2011","unstructured":"Liss\u00a0MA, Chang\u00a0A, Santos\u00a0R et\u00a0al (2011) Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J\u00a0Urol 185:1283\u20131288","journal-title":"J Urol"},{"key":"1618_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","volume":"198","author":"MA Liss","year":"2017","unstructured":"Liss\u00a0MA, Ehdaie\u00a0B, Loeb\u00a0S et\u00a0al (2017) An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J\u00a0Urol 198:329\u2013334","journal-title":"J Urol"},{"key":"1618_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41391-018-0032-2","volume":"21","author":"J Noreikaite","year":"2018","unstructured":"Noreikaite\u00a0J, Jones\u00a0P, Fitzpatrick\u00a0J et al (2018) Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a\u00a0systematic review and meta-analysis. Prostate Cancer Prostatic Dis 21:153\u2013160","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1618_CR19","doi-asserted-by":"publisher","first-page":"k678","DOI":"10.1136\/bmj.k678","volume":"360","author":"B Pasternak","year":"2018","unstructured":"Pasternak\u00a0B, Inghammar\u00a0M, Svanstr\u00f6m\u00a0H (2018) Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 360:k678","journal-title":"BMJ"},{"key":"1618_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/JU.0000000000000814","volume":"204","author":"A Pilatz","year":"2020","unstructured":"Pilatz\u00a0A, Dimitropoulos\u00a0K, Veeratterapillay\u00a0R et al (2020) Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J\u00a0Urol 204:224\u2013230","journal-title":"J Urol"},{"key":"1618_CR21","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/jac\/dkv067","volume":"70","author":"NJ Rhodes","year":"2015","unstructured":"Rhodes\u00a0NJ, Gardiner\u00a0BJ, Neely\u00a0MN et al (2015) Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J\u00a0Antimicrob Chemother 70:2068\u20132073","journal-title":"J Antimicrob Chemother"},{"key":"1618_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijantimicag.2014.01.008","volume":"43","author":"MJ Roberts","year":"2014","unstructured":"Roberts\u00a0MJ, Williamson\u00a0DA, Hadway\u00a0P et al (2014) Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents 43:301\u2013309","journal-title":"Int J Antimicrob Agents"},{"key":"1618_CR23","doi-asserted-by":"publisher","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","volume":"7","author":"LL Silver","year":"2017","unstructured":"Silver\u00a0LL (2017) Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med 7:a25262","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1618_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1469-0691.2011.03638.x","volume":"18","author":"D Steensels","year":"2012","unstructured":"Steensels\u00a0D, Slabbaert\u00a0K, De Wever\u00a0L et al (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy\u2014Should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 18:575\u2013581","journal-title":"Clin Microbiol Infect"},{"key":"1618_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.urology.2015.07.008","volume":"86","author":"VL Tchesnokova","year":"2015","unstructured":"Tchesnokova\u00a0VL, Ottley\u00a0LL, Sakamoto\u00a0K et al (2015) Rapid identification of rectal multidrug-resistant Escherichia coli before transrectal prostate biopsy. Urology 86:1200\u20131205","journal-title":"Urology"},{"key":"1618_CR26","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.21037\/tau.2019.12.40","volume":"9","author":"A Thomson","year":"2020","unstructured":"Thomson\u00a0A, Li\u00a0M, Grummet\u00a0J et\u00a0al (2020) Transperineal prostate biopsy: a\u00a0review of technique. Transl Androl Urol 9:3009\u20133017","journal-title":"Transl Androl Urol"},{"issue":"9","key":"1618_CR27","doi-asserted-by":"publisher","first-page":"e00253-18","DOI":"10.1128\/JCM.00253-18","volume":"56","author":"SCM Tops","year":"2018","unstructured":"Tops\u00a0SCM, Bruens\u00a0M, Van Mook-Vermulst\u00a0S et al (2018) Performance validation of selective screening agars for guiding antimicrobial prophylaxis in patients undergoing prostate biopsy. J\u00a0Clin Microbiol 56(9):e00253-18","journal-title":"J Clin Microbiol"},{"key":"1618_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrurol.2013.322","volume":"11","author":"FM Wagenlehner","year":"2014","unstructured":"Wagenlehner\u00a0FM, Pilatz\u00a0A, Waliszewski\u00a0P et\u00a0al (2014) Reducing infection rates after prostate biopsy. Nat Rev Urol 11:80\u201386","journal-title":"Nat Rev Urol"},{"key":"1618_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.urology.2019.10.008","volume":"136","author":"C Wurnschimmel","year":"2020","unstructured":"Wurnschimmel\u00a0C, Busto Martin\u00a0L, Leyh-Bannurah\u00a0SR et al (2020) Rectal swabs for detecting multidrug resistant bacteria prior to transrectal prostate fusion biopsy: a prospective evaluation of risk factor screening and microbiologic findings. Urology 136:127\u2013132","journal-title":"Urology"},{"key":"1618_CR30","first-page":"CD006576","volume":"5","author":"EL Zani","year":"2011","unstructured":"Zani\u00a0EL, Clark\u00a0OA, Rodrigues Netto\u00a0N Jr (2011) Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 5:CD6576","journal-title":"Cochrane Database Syst Rev"},{"key":"1618_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12879-017-2470-1","volume":"17","author":"TR Zembower","year":"2017","unstructured":"Zembower\u00a0TR, Maxwell\u00a0KM, Nadler\u00a0RB et\u00a0al (2017) Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a\u00a0prospective cohort trial. BMC Infect Dis 17:401","journal-title":"BMC Infect Dis"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01618-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T12:03:13Z","timestamp":1644494593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01618-1"}},"subtitle":["Im Kontext von Fluorchinolon-Indikationsr\u00fccknahme und Antibiotic Stewardship"],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01618-1","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"30 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Rothe, C.\u00a0Querbach, D.H.\u00a0Busch, J.E.\u00a0Gschwend und K.\u00a0Hauner geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}